+49 2641 3703 – 0 +49 2641 3703 – 199 info@monch-group.com

US DoD Funds Israeli Medical Diagnostic Development

MeMed Receives $9.2 Million Contract from DTRA

Haifa-based MeMed, a developer of devices to monitor the body’s immune state, announced on 19 April it has received a $9.2 million contract from the US Defense Threat Reduction Agency (DTRA) to complete development of a bedside device that will help distinguish between viral and bacterial infections.

Established in 1998 to integrate DoD activities addressing the threat of weapons of mass destruction, DTRA supports R&D activities that offer solutions to the often intractable problems presented by the covert use of such weapons against civilian or societal targets. It support of MeMed research aims to accelerate development of a next generation test and monitoring solution that exploits work the company has conducted over the last eight years.
“This joint effort, and our growing collaboration with other international stakeholders from industry and government, will facilitate the global availability of our tests aimed at combating antimicrobial resistance,” MeMed CEO, Eran Eden, stated.

 

Related Posts

Publish date

04/21/2017

Sign up to our newsletter and stay up to date.

News

Air

C4ISR

Components / Systems

Cyber

Defence Business

Homeland Security

International Security

Land

Latin America (Spanish)

Logistics

Naval

Training & Simulation

Space

Special Forces

Unmanned

Publications

Contact Us

Contact Info

Mönch Verlagsgesellschaft mbH
Christine-Demmer-Straße 7
53474 Bad Neuenahr – Ahrweiler

+49 2641 3703 – 0

+49 2641 3703 – 199

Follow On

X